We have the creme de la creme of a mega partner with TEVA . Bio-T-Gel will drive BPAX into profitability and we have still more than 20 drugs in pipeline many of them in late stage 7 drugs of them have BLOCKBUSTER POTENTIAL !!!!
Back to $2++ quickly after FDA approval .Hold your shares folks !
Bio-T-Gel™ is a once-daily transdermal testosterone gel in development for the treatment of male hypogonadism, or low testosterone levels. Male hypogonadism generally is characterized by impotence, a lack of sex drive, muscle weakness and osteoporosis. In 2010, the transdermal testosterone market for men in the U.S. was over $1.2 billion.
Bio-T-Gel™ is licensed to Teva Pharmaceuticals, USA. A Bio-T-Gel™ NDA is pending with the FDA having a PDUFA date of February 14, 2012. Teva is responsible for all regulatory and marketing activities.